Welcome to the e-CCO Library Archive!
P691
Frequency of anaemia and anaemia subtypes in east-west European inception cohort: an ECCO-EpiCom cohort study
J. Burisch*1, U. Gerdes2,3, S. Almer4, S. Čuković-Čavka5, S. Sebastian6, I. Kaimakliotis7, D. Duricova8, N. Pedersen9, R. Salupere10, K. R. Nielsen11,12, P. Manninen13, K. H. Katsanos14, S. Odes15, V. Andersen16,17, R. D’Inca18, L. Kupcinskas19, S. Turcan20, F. Magro21, 22, 23, A. Goldis24, K. Kofod Vinding25, E. Belousova26, K. Ladefoged27, Y. Bailey28, V. Hernandez29, J. Halfvarson30, N. Arebi31, O. Shonova32, M. L. Hoivik33, B. Moum34, E. Langholz35, P. L. Lakatos36, P. Munkholm1, J. F. Dahlerup37
1North Zealand University Hospital, Department of Gastroenterology, Frederikssund, Denmark, 2Region of Southern Denmark, Centre for Quality, Middelfart, Denmark, 3University of Southern Denmark, Institute of Regional Health Research, Odense, Denmark, 4County council of Östergötland, Department of Gastroenterology/UHL, Linköping, Sweden, 5University Hospital Centre Zagreb, University of Zagreb School of Medicine, Division of Gastroenterology and Hepatology, Zagreb, Croatia, 6Hull Royal Infirmary, Hull and East Yorkshire NHS Trust & Hull and York Medical School, Hull, United Kingdom, 7Nicosia Private practice, Nicosia Private practice, Nicosia, Cyprus, 8Charles University, IBD Centre ISCARE, Prague, Czech Republic, 9Slagelse Hospital, Department of Gastroenterology, Slagelse, Denmark, 10Tartu University Hospital, Division of Endocrinology and Gastroenterology, Tartu, Estonia, 11The National Hospital of the Faroe Islands, Medical department, Tórshavn, Faroe Islands, 12Genetic Biobank, Tórshavn, Faroe Islands, 13Tampere University Hospital, Department of Gastroenterology and Alimentary Tract Surgery, Tampere, Finland, 14University Hospital, Ioannina, 1st Division of Internal Medicine and Hepato-Gastroenterology Unit, Ioannina, Greece, 15Soroka Medical Centre and Ben-Gurion University of the Negev, Department of Gastroenterology and Hepatology, Beer Sheva, Israel, 16Viborg Regional Hospital, Medical Department, Viborg, Denmark, 17Hospital of Southern Jutland, Medical Department, Aabenraa, Denmark, 18On behalf of the EpiCom Northern Italy, Florence, Forlì, and Padova, Northern Italy, Italy, 19Lithuanian University of Health Sciences, Institute for Digestive Research, Kaunas, Lithuania, 20State University of Medicine and Pharmacy of the Republic of Moldova, Department of Gastroenterology, Chisinau, Moldova, Republic of, 21University of Porto, Institute for molecular and cell biology, Porto, Portugal, 22Hospital de São João, Department of Gastroenterology, Porto, Portugal, 23Oporto Medical School, Institute of Pharmacology and Therapeutics, Porto, Portugal, 24University of Medicine ‘Victor Babes’, Clinic of Gastroenterology, Timisoara, Romania, 25Amager Hospital, Department of medicine, Amager, Denmark, 26Moscow Regional Research Clinical Institute, Department of Gastroenterology, Moscow, Russian Federation, 27Dronning Ingrids Hospital, Medical Department, Nuuk, Greenland, 28Adelaide and Meath Hospital, TCD, Department of Gastroenterology, Dublin, Ireland, 29Complexo Hospitalario Universitario de Vigo, Gastroenterology Department, Vigo, Spain, 30Faculty of Medicine and Health, Örebro University, Department of Gastronterology, Örebro, Sweden, 31St Mark’s Hospital, Gastroenterology, London, United Kingdom, 32Nemocnice Ceske Budejovice, Department of Gastroenterology, Ceske Budejovice, Czech Republic, 33Oslo University Hospital, Department of Gastroenterology, Oslo, Norway, 34Oslo University Hospital, Department of Gastroenterology, Oslo, Norway, 35Gentofte Hospital, Department of Medical Gastroenterology, Copenhagen, Denmark, 36Semmelweis University, 1st Department of Medicine, Budapest, Hungary, 37Aarhus University Hospital, Department of Hepatology and Gastroenterology, Aarhus, Denmark
P692
Co-exposure of microscopic colitis-associated drugs does not affect paracellular permeability in vitro
B. P. M. Verhaegh*1, 2, F. de Vries3, 4, D. Keszthelyi1, J. G. Kuiper5, A. A. M. Masclee1, 2, M. J. Pierik1, D.M.A.E. Jonkers1, 2
1Maastricht University Medical Centre+, Internal Medicine - Division of Gastroenterology-Hepatology, Maastricht, Netherlands, 2Maastricht University Medical Centre+, NUTRIM, School of Nutrition and Translational Research in Metabolism, Maastricht, Netherlands, 3Utrecht Institute of Pharmaceutical Sciences, Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht, Netherlands, 4Maastricht University Medical Centre+, Department of Clinical Pharmacology & Toxicology, Maastricht, Netherlands, 5PHARMO Institute of Drug Outcomes Research, Utrecht, Netherlands
P693
Inflammatory bowel disease in Norway 1999 to 2014: increasing prevalence and local geographical differences
M. L. Hoivik*1, B. Moum2, T. Glomsaker3
1Oslo University Hospital, Department of Gastroenterology, Oslo, Norway, 2Oslo University Hospital, Department of Gastroenterology, Oslo, Norway, 3Oslo University Hospital, Department of Surgery, Oslo, Norway
P694
Nationwide prevalence of inflammatory bowel diseases in Hungary: a population-based study based on the National Health Insurance Fund database
Z. Kurti*1, L. Gonczi1, P. A. Golovics1, B. Lovasz1, P. Fadgyas-Freyler2, J. Gimesi-Orszagh2, G. B. Korponai2, Z. Vegh1, P. Lakatos1
1Semmelweis University, First Department of Medicine, Budapest, Hungary, 2National Health Insurance Fund (OEP), Strategic Analysis Department, Budapest, Hungary
P695
Use of infliximab and associated costs in inflammatory bowel disease patients: an analysis of real-life health claims data in the Netherlands
D. Hoekman*1, S. Bots2, M. Benninga1, H. Smeets3, G. D’Haens2, M. Löwenberg2
1Academic Medical Centre (AMC), Department of Paediatric Gastroenterology, Amsterdam, Netherlands, 2Academic Medical Centre (AMC), Department of Gastroenterology, Amsterdam, Netherlands, 3Achmea Health Insurance, Amersfoort, Netherlands
P696
First results and information model from the Parelsnoer Institute IBD biobank: a nationwide standardised inflammatory bowel disease collection by all university medical centres in the Netherlands
L. M. Spekhorst*1, 2, F. Imhann1, 2, E. A. M. Festen1, 2, A. A. van Bodegraven3, N. K. H. de Boer3, G. Bouma3, H. H. Fidder4, G. R. A. M. D’Haens5, F. Hoentjen6, D. W. Hommes7, D. J. de Jong6, M. Lowenberg5, A.E. van der Meulen-de Jong7, B. Oldenburg4, M. Pierik8, C.Y. Ponsioen5, P.C. Stokkers9, M. C. Visschedijk1, 2, C. J. van der Woude10, G. Dijkstra1, R. K. Weersma1
1University of Groningen and University Medical Centre Groningen, Department of Gastroenterology and Hepatology, Groningen, Netherlands, 2University of Groningen and University Medical Centre Groningen, Department of Genetics, Groningen, Netherlands, 3VU University Medical Centre, Department of Gastroenterology and Hepatology, Amsterdam, Netherlands, 4University Medical Centre Utrecht, Department of Gastroenterology and Hepatology, Utrecht, Netherlands, 5Amsterdam Medical Centre, Department of Gastroenterology and Hepatology, Amsterdam, Netherlands, 6University Medical Centre St Radboud, Department of Gastroenterology and Hepatology, Nijmegen, Netherlands, 7Leiden University Medical Centre, Department of Gastroenterology and Hepatology, Leiden, Netherlands, 8University Medical Centre Maastricht, Division of Gastroenterology and Hepatology, Maastricht, Netherlands, 9St Lucas Andreas Ziekenhuis, Department of Gastroenterology and Hepatology, Amsterdam, Netherlands, 10Erasmus Medical Centre, Department of Gastroenterology and Hepatology, Rotterdam, Netherlands
P697
Highlighting of epidemic areas of Crohn’s disease in a population-based registry over 22 years: genetic or environmental cause?
M. Genin*1, 2, C. Vignal1, 3, F. Vasseur2, M. Fumery4, G. Savoye5, M. Body-Malapel1, 3, C. Preda6, H. Sarter7, L. Peyrin-Biroulet8, P. Desreumaux3, 9, C. Gower-Rousseau1, 7, 10
1University Hospital, Lille, France, 2CHRU Lille, Department of Biostatistics EA 2694, Lille, France, 3Inserm 995 LIRIC Team 5, Lille, France, 4University Hospital, Gastroenterology, Amiens, France, 5University Hospital, Gastroenterology, Rouen, France, 6UFR de Mathématiques, Lille, France, 7University, Inserm 995 LIRIC Team 5, Lille, France, 8University Hospital, Gastroenterology, Nancy, France, 9University Hospital, Gastroenterology, Lille, France, 10CHRU Lille, Department of Epidemiology, EPIMAD Registry, Lille, France
P698
Incidence and disease course of inflammatory bowel disease diagnosed incidentally during a colorectal cancer screening programme: A retrospective multicentre study— preliminary results
I. Rodríguez-Lago*1, 2, O. Merino2, 3, J. Carrascosa2, 4, M. Fernández - Calderón2, 5, A. Maiz2, 6, A. Muñagorri2, 7, P. Arreba2, 8, R. Higuera2, 9, E. Zapata2, 10, I. Moraleja1, 2, I. Montalvo2, 11, I. Portillo12, J. L. Cabriada1, 2
1Galdakao Hospital, Gastroenterology, Galdakao, Spain, 2IBD Study Group of the Basque – Navarre Society of Gastrointestinal Diseases, Pais Vasco - Navarra, Spain, 3Cruces University Hospital, Gastroenterology, Bilbao, Spain, 4Zumárraga Hospital, Gastroenterology, Zumárraga, Spain, 5Mondragon - Alto Deba Hospital, Gastroenterology, Mondragón, Spain, 6Donostia Hospital, Microbiology, Donostia, Spain, 7Donostia Hospital, Gastroenterology, Donostia, Spain, 8Basurto University Hospital, Gastroenterology, Bilbao, Spain, 9San Eloy Hospital, Gastroenterology, Bilbao, Spain, 10Mendaro Hospital, Gastroenterology, Mendaro, Spain, 11Onkologikoa Hospital, Gastroenterology, Donostia, Spain, 12Basque Country Health Service, Colorectal cancer screening programme, Bilbao, Spain
P699
Health-related quality of life in inflammatory bowel disease in a Danish population-based inception cohort
L. Christiansen*, F. Bendtsen, J. Burisch, M. Kajbaek Vester-Andersen
Hvidovre University Hospital, Department of Gastroenterology, Hvidovre, Denmark
P700
Incidence and phenotype at diagnosis in very early-onset paediatric inflammatory bowel disease: a population-based study (1988–2011)
E. Bequet1, H. Sarter2, M. Fumery3, L. Armengol-Debeir4, B. Pariente5, D. Ley6, C. Spyckerelle7, H. Coevoet8, L. Peyrin-Biroulet9, G. Savoye*10, T. Dominique6, C. Gower-Rousseau11
1Centre Hospitalier Régional Universitaire, Gastroentérologie pédiatrique, Lille, France, 2Chru, Epidémiologie, Lille, France, 3Université d’Amiens, Gastroentérologie, Amiens, France, 4Université de Rouen, Gastroentérologie, Rouen, France, 5chru, Gastoentérologie, Lille, France, 6Chru, Gastroentérologie pédiatrique, Lille, France, 7Hopital Saint-Vincent - Université catholique, Pédiatrie, Lille, France, 8Hôpital Les bonnettes, Arras, France, 9Chu, Gastroentérologie, Nancy, France, 10Chu Rouen, Gastroentérologie, Rouen, France, 11Chru, Lille, France
P701
Prevalence of positive anti-tissue transglutaminase antibodies in inflammatory bowel disease patients
F. Casellas*1, 2, C. Herrera de Guise1, V. Robles1, N. Borruel1
1Hospital Universitari Vall d’Hebron, Unitat Atenció Crohn-Colitis, Barcelona, Spain, 2Hospital Universitari Vall d’Hebron, Barcelona, Spain
P702
The effect of disease activity on adverse birth outcomes in a nationwide cohort of woman treated with biologics for chronic inflammatory bowel disease during pregnancy
H. Kammerlander*1, J. Nielsen1, J. Kjeldsen2, T. Knudsen3, S. Friedman4, B. Nørgård1
1University of Southern Denmark, Centre for Clinical Epidemiology, Odense, Denmark, 2University of Southern Denmark, Department of Medical Gastroenterology, Odense, Denmark, 3University of Southern Denmark, Department of Medical Gastroenterology, Esbjerg, Denmark, 4Massachusetts and Harvard Medical School, 4. Crohn’s and Colitis Centre, Brigham and Women’s Hospital, Boston, United States
P703
De-novo inflammatory bowel disease is a significant risk factor for primary sclerosing cholangitis recurrence after liver transplantation
L. Bajer*1, E. Sticova2, P. Macinga1, R. Janousek3, P. Trunecka4, J. Spicak1, P. Drastich1
1Institute for Clinical and Experimental Medicine, Hepatogastroenterology, Prague, Czech Republic, 2Institute for Clinical and Experimental Medicine, Pathology, Prague, Czech Republic, 3Institute for Clinical and Experimental Medicine, Radiology, Prague, Czech Republic, 4Institute for Clinical and Experimental Medicine, Transplantcentre, Prague, Czech Republic
P704
Dairy products, dietary calcium and the risk of inflammatory bowel disease: results from a European prospective cohort investigation
J. Opstelten*1, M. Leenders1, V. Dik1, S. Chan2, 3, F. van Schaik1, P. Siersema1, B. Bueno-de-Mesquita1, 4, 5, 6, A. Hart2, 3, B. Oldenburg1
1University Medical Centre Utrecht, Department of Gastroenterology and Hepatology, Utrecht, Netherlands, 2Norfolk and Norwich University Hospital NHS Trust, Department of Gastroenterology, Norwich, United Kingdom, 3University of East Anglia, Norwich Medical School, Department of Medicine, Norwich, United Kingdom, 4National Institute for Public Health and the Environment (RIVM), Department for Determinants of Chronic Diseases, Bilthoven, Netherlands, 5Imperial College London, School of Public Health, Department of Epidemiology and Biostatistics, London, United Kingdom, 6University of Malaya, Faculty of Medicine, Department of Social and Preventive Medicine, Kuala Lumpur, Malaysia
P705
Long-term outcomes and predictors of disabling disease of a population-based cohort of incident Crohn’s disease diagnosed between 1995 and 1997
M.-L. Rabilloud*1, J.-F. Bretagne1, E. Bajeux2, L. Siproudhis3, J.-F. Viel2, I. Tron4, M. Robaszkiewicz5, G. Bouguen1
1Université Rennes 1 & CHU Pontchaillou Rennes, Service des Maladies de l’Appareil Digestif, Rennes, France, 2CHU Pontchaillou, Service de Santé Publique, Rennes, France, 3Université Rennes 1 & CHU Pontchaillou Rennes, Service de chirurgie digestive, Rennes, France, 4ORSB, Rennes, France, 5CHU Brest, La Cavale Blanche, Service des Maladies de l’Appareil Digestif, Brest, France
P706
The long-term risk of complicated gallstone disease necessitating cholecystectomy after ileal resection in Crohn’s disease patients
J. C. Goet*1, B. E. Hansen1, K. Bierman2, A. Gijsbers3, C. J. van der Woude1, W. R. Schouten4, H. R. van Buuren1, A.C. de Vries1
1Erasmus MC, Gastroenterology and Hepatology, Rotterdam, Netherlands, 2Erasmus MC, Pathology, Rotterdam, Netherlands, 3PALGA, Rotterdam, Netherlands, 4Erasmus MC, Surgery, Rotterdam, Netherlands
P707
Healthcare expectations of patients with inflammatory bowel disease: a survey amongst 1 089 participants in a European bilingual clinical cohort
V. Pittet*1, C. Vaucher1, M. H. Maillard2, F. Froehlich3, B. Burnand1, P. Michetti4
1Institute of Social and Preventive Medicine, Healthcare Evaluation Unit, Lausanne, Switzerland, 2Lausanne University Hospital, Department of Gastroenterology & Hepatology, Lausanne, Switzerland, 3University Hospital Basel, Division of Gastroenterology & Hepatology, Basel, Switzerland, 4Clinique La Source-Beaulieu, Crohn and Colitis Centre, Lausanne, Switzerland
P708
Determinants of job stress in patients with inflammatory bowel disease
P. Schreiner*1, L. Biedermann2, J.-B. Rossel3, V. Pittet4, R. von Känel5
1UniversityHospital of Zurich, Internal Medicine, Zurich, Switzerland, 2UniversityHospital of Zurich, Gastroenterology and Hepatology, Zurich, Switzerland, 3Lausanne University Hospital, Lausanne, Switzerland, 4Lausanne University Hospital, Institute of Social & Preventive Medicine, Lausanne, Switzerland, 5Clinic Barmelweid, Department of Psychosomatic Medicine, Barmelweid, Switzerland
P709
Patients’ perceptions on patient-physician communication and influence of hospital size amongst Spanish patients with ulcerative colitis: UC-LIFE survey
X. Calvet*1, A. López-Sanromán2, F. Argüelles-Arias3, L. Cea-Calvo4, B. Juliá4, C. Romero4, D. Carpio5
1Corporació Sanitària Universitària Parc Taulí, Digestive Disease Department. Departament de Medicina. Universitat Autònoma de Barcelona. CIBEREHD – Instituto de Salud Carlos III, Sabadell, Spain, 2Hospital Ramón y Cajal, Gastroenterology and Hepatology Department, Madrid, Spain, 3Hospital Universitario Virgen Macarena, Gastroenterology Unit, Sevilla, Spain, 4Merck Sharp & Dohme de España, Medical Affairs, Madrid, Spain, 5Complexo Hospitalario Universitario, Gastroenterology Department, Instituto de Investigación Biomédica (IBI). Xerencia de Xestión Integrada de Pontevedra. SERGAS, Pontevedra, Spain
P710
Evolution of the incidence of inflammatory bowel disease in the south of Spain in 2 periods
D. Chaaro*1, J. M. Benitez2, R. Perea Amarillo1, F. Argüelles Arias1, L. Castro Laria1, M. B. Maldonado Perez1, V. García Sanchez2, E. Iglesias Flores2, A. Benitez Roldan1, A. Caunedo Álvarez1
1University Hospital Virgen Macarena, Gastroenterology and Hepatology Department, Seville, Spain, 2University Hospital Reina Sofía, Gastroenterology and Hepatology Department, Cordoba, Spain